Delivery Order SPE2DB22D2007-SPE2DB25FJ5JY
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $7,391.80 delivery order for Padcev 20 mg vials under a firm fixed-price contract with an ultimate completion date of August 11, 2025. This is a non-set-aside award, meaning it was competitively awarded without restrictions. The order will be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company operates as a major pharmaceutical distributor serving federal medical procurement needs,...
- The Defense Logistics Agency awarded a $11,087.60 delivery order to AmerisourceBergen Drug Corp for Padcev 30 mg vials, with an ultimate completion date of August 8, 2025. This is a firm fixed-price, non-set-aside contract with performance in Conshohocken, Pennsylvania. The delivery order was awarded on July 18, 2025, as part of AmerisourceBergen's broader engagement with the federal government for pharmaceutical supply. This delivery order falls under AmerisourceBergen's substantial...
- The Defense Logistics Agency awarded a $11,087.70 delivery order to AmerisourceBergen Drug Corp for the supply of Padcev 20 mg vials, with performance to be completed by September 23, 2025. This competitively awarded, firm fixed-price contract is being executed from the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $27,719 to AmerisourceBergen Drug Corp for 30 mg vials of Padcev, a oncology treatment, with performance at the company's Conshohocken, Pennsylvania facility. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 2, 2025. As a non-set-aside contract, the award reflects AmerisourceBergen's demonstrated capability to compete successfully in federal pharmaceutical...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order award on September 15, 2025, for Padcev 30 mg vials with a ceiling value of $83,157.00. This firm fixed price contract, issued by the Defense Logistics Agency's Medical Supply Chain, represents a competitively awarded procurement with no set-aside designation and is scheduled for completion by October 6, 2025. The contract is structured as a child delivery...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of PADCEV 30 mg vials, a specialized pharmaceutical product. This firm fixed-price delivery order carries a ceiling value of $27.7K and is scheduled for completion by August 4, 2025. The contract was awarded competitively with no set-aside designation, and performance will occur at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $11,087.70 to AmerisourceBergen Drug Corp for the supply of Padcev 20 mg vials. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 19, 2025, and carries no set-aside designation. The contract will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider,...
- The Defense Logistics Agency awarded a delivery order valued at $11,087.60 to AmerisourceBergen Drug Corp for the supply of Padcev 30 mg vials. This competitively awarded, firm fixed price contract was executed on September 2, 2025, with an ultimate completion date of September 23, 2025. The pharmaceutical distributor will perform the delivery at its corporate office location in Conshohocken, Pennsylvania. As a non-set-aside procurement, this award reflects AmerisourceBergen's continued...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $8,315.70 to supply PADCEV 30 mg vials, a pharmaceutical product for oncology treatment. This is a firm fixed-price delivery order with an ultimate completion date of September 26, 2025, and was competitively awarded with no set-aside designation. The work will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $27,719 on July 28, 2025, for the supply of Padcev 30 mg vials. This firm fixed-price delivery order, which is expected to be completed by August 18, 2025, was issued without a set-aside designation, indicating it was competitively awarded. The contract is performed at the awardee's Corporate Office location in Conshohocken, PA and is funded...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ5JYDelivery Order
The Defense Logistics Agency awarded a $22,175.20 delivery order to AmerisourceBergen Drug Corp for Padcev 30 mg vials, with an ultimate completion date of October 20, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as the company's primary vehicle for supplying pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, maintains a substantial federal contract portfolio focused on supplying critical medications and medical commodities to the Defense Health Agency and other military healthcare systems. Padcev (ado-trastuzumab emtansine) is an oncology therapeutic used in cancer treatment, consistent with AmerisourceBergen's role as a comprehensive pharmaceutical vendor for specialized healthcare needs within the federal medical supply chain. The company's extensive experience fulfilling competitively awarded contracts across multiple therapeutic domains, combined with its primary vendor status through the DLA Troop Support Medical IDC, positions it as a critical supplier for military pharmaceutical procurement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.2k | 9/26/25 |